Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

Core Insights - Corcept Therapeutics Incorporated is a commercial-stage company focused on developing medications targeting severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol effects [1] Company Developments - The company will present new data from its pivotal Phase 3 ROSELLA trial, which investigates the combination of relacorilant and nab-paclitaxel for treating platinum-resistant ovarian cancer [1] - The presentation is scheduled for the 2025 European Society for Medical Oncology [1]